Allogene Therapeutics Inc (ALLO) Stock Up 2.61%: Is It a Good Investment?

Allogene Therapeutics Inc [ALLO] stock is trading at $1.18, up 2.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALLO shares have gain 3.51% over the last week, with a monthly amount glided 7.27%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on May 14, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, Citizens JMP upgraded its rating to Mkt Outperform on March 14, 2025, and kept the price target unchanged to $5. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $11 on May 31, 2024. JMP Securities downgraded its rating to a Mkt Perform. Guggenheim downgraded its rating to Neutral for this stock on January 05, 2024. In a note dated December 08, 2023, Citigroup initiated a Buy rating and provided a target price of $7 on this stock.

Allogene Therapeutics Inc [ALLO] stock has fluctuated between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.18 at the most recent close of the market. An investor can expect a potential return of 2357.63% based on the average ALLO price forecast.

Analyzing the ALLO fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.59 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.23.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

For context, Allogene Therapeutics Inc’s Current Ratio is 8.92. Also, the Quick Ratio is 8.92, while the Cash Ratio stands at 1.65.

Transactions by insiders

Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Jun 10 ’25 when 36885.0 shares were sold. Director, MESSEMER DEBORAH M. completed a deal on Jun 10 ’25 to buy 36885.0 shares. Meanwhile, SVP, Finance Yoshiyama Annie sold 9601.0 shares on Apr 21 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.